The evidence on peptides — delivered weekly. Subscribe free →

TB-500

low risk

Also: Thymosin Beta-4 · Tβ4 · Thymobeta-4

Moderate Evidence Research Only

Thymosin Beta-4 (TB-500 is the synthetic fragment) has potent tissue repair, anti-inflammatory, and angiogenic properties. Human Phase II trials exist for cardiac repair and wound healing. WADA-prohibited due to performance-enhancing potential.

Molecular Weight
4963.5 Da
Formula
C212H350N56O78S
Common Dosing
2–2.5 mg twice weekly SC, 4–6 week loading then maintenance
Category
therapeutic
Last Reviewed
2025-01-15

Reported Benefits

Wound healing

Moderate Evidence 31 studies

Human Phase II trials in chronic dermal wounds show accelerated closure.

Cardiac repair

Moderate Evidence 18 studies

Phase II trial showed improved cardiac function post-MI.

Anti-inflammatory

Moderate Evidence 23 studies

Reduces TNF-α, IL-1β in multiple models.

Mechanism of Action

Sequesters G-actin; upregulates VEGF, MMP-2, KGF-1; promotes stem cell differentiation and mobilization to injury sites.

Key Clinical Studies

Sosne et al. (2010)

RCT · Phase II

PubMed →

Improved wound healing in chronic dermal wounds

Frequently Asked Questions

What injuries does TB-500 help with? ▾
TB-500 (Thymosin Beta-4 synthetic fragment) has preclinical evidence for accelerating healing of muscle tears, tendon injuries, ligament damage, and skin wounds. It has also shown anti-inflammatory effects in cardiac tissue (post-infarction models) and neuroprotective properties. Human clinical data is limited but Phase II cardiac trials have been conducted.
How fast does TB-500 work for injury recovery? ▾
Animal studies document measurable tissue repair acceleration within 1–2 weeks. Human anecdotal reports most commonly describe acute injury recovery improvement within 2–4 weeks of consistent dosing. Chronic or significant injuries typically require 6–12 weeks of a full protocol.
What is the difference between TB-500 and BPC-157? ▾
TB-500 is a synthetic analog of Thymosin Beta-4, a systemic peptide with broad anti-inflammatory and actin-regulatory properties affecting muscle, cardiac, and connective tissue. BPC-157 is a gastric peptide with stronger specificity for gut and tendon-to-bone junction healing. They have overlapping but not identical mechanisms, and are frequently combined for musculoskeletal repair.
What is the proper TB-500 dosing protocol? ▾
Research protocols commonly reference a loading phase of 2–2.5 mg twice weekly for 4–6 weeks, followed by a maintenance phase of 2–2.5 mg once weekly or biweekly. TB-500 is administered subcutaneously or intramuscularly. No human pharmacokinetic dose-finding studies have been completed.
Is TB-500 the same as Thymosin Beta-4? ▾
TB-500 is a synthetic analog of the C-terminal fragment of Thymosin Beta-4, not the full peptide. The full Thymosin Beta-4 protein is 43 amino acids; TB-500 corresponds to the active sequence fragment. Research properties are similar but not identical. TB-500 is the form commonly available for research use.

Human Evidence Context

Unlike most research peptides, TB-500/Thymosin Beta-4 has completed Phase II clinical trials for cardiac indications and wound healing, giving it one of the more credible human evidence bases in the non-approved peptide space.

WADA Prohibition

TB-500 is on the World Anti-Doping Agency’s prohibited list — itself a signal that WADA considers the performance-enhancing potential real enough to regulate.

✦ Sponsored

Stop Guessing About Your Health. Start Optimizing It.

Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.

Learn More →
Nava Health

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Fatigue (loading phase)
  • •Injection site reactions
  • •Headache

Contraindications

  • •Active malignancy
  • •Pregnancy

Primary Uses

Wound healingMuscle repairAnti-inflammatoryAngiogenesis

Related Peptides

BPC-157LL-37IGF-1 LR3

Used For

›Tissue Repair & Recovery

Planning a protocol?

Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.

Stack Builder → Protocol Builder →

Weekly Briefing

Regulatory updates + new study breakdowns.

Related Articles

› BPC-157 and Gut Health: Reviewing the IBD and NSAID Injury Evidence › The FDA's Warning Letter Pattern: Which Peptide Vendors Are Getting Targeted and Why › The Regulatory Status of Research Peptides: A Practitioner's Primer

For Practitioners

Do you prescribe TB-500?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.